C&EN White Paper
Picking the right CDMO partner for integrated and accelerated peptide therapeutic development
Brought to you by WuXi STA
Overview

Peptides have emerged as valuable therapeutics due to their attractive drug properties and are being developed to treat ailments ranging from cancer to diabetes. With many new therapeutic peptides in the development pipeline, the peptide market is expected to continue to expand in upcoming years. However, the full potential of this class of therapeutics has yet to be realized due to challenges associated with their development and production.

Partnering with specialists including contract development and manufacturing organizations (CDMOs) can help innovators overcome hurdles associated with therapeutic peptide development and production. CDMOs possess the capability, capacity, and expertise to help partners achieve the output they need to move their peptides through the research and clinical trial stages and, ultimately, to market. This white paper from WuXi STA highlights the versatile services and capabilities a CDMO can provide as a partner during peptide development and manufacturing.

Key Objectives:
  • Why peptides are promising therapeutics and the challenges faced during development
  • How partnering with a CDMO can facilitate effective development and production strategies to overcome hurdles
  • What to consider and how to make decisions surrounding selecting a CDMO partner

Brought to you by:
WuXi STA
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

Copyright © 2022 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy